Table V.

ELAC2 SNP and haplotypes and risk of aggressive and non-aggressive prostate cancer

	Non-carriers		Carriers		P-value*
	Cases/controls	OR	Cases/controls	OR (95% CI)
SNP
Aggressive prostate cancer
Snp1	158/447	1.00	78/198	1.10 (0.80–1.52)	0.55
Snp2	94/314	1.00	141/331	1.43 (1.06–1.93)	0.02
Snp3	76/161	1.00	157/476	0.69 (0.50–0.95)	0.03
Snp4	152/370	1.00	83/273	0.74 (0.54–1.01)	0.05
Snp5	112/296	1.00	122/348	0.92 (0.68–1.24)	0.57
Snp6	174/472	1.00	58/167	0.93 (0.66–1.32)	0.69
Snp8	172/487	1.00	63/157	1.13 (0.80–1.58)	0.50
Non-aggressive prostate cancer
Snp1	270/447	1.00	141/198	1.18 (0.91–1.54)	0.21
Snp2	194/314	1.00	216/331	1.06 (0.83–1.36)	0.65
Snp3	103/161	1.00	304/476	1.00 (0.75–1.34)	0.98
Snp4	224/370	1.00	184/273	1.11 (0.87–1.43)	0.40
Snp5	196/296	1.00	213/348	0.92 (0.72–1.19)	0.53
Snp6	306/472	1.00	103/167	0.95 (0.72–1.26)	0.73
Snp8	300/487	1.00	110/157	1.14 (0.86–1.51)	0.37
Haplotype
Aggressive prostate cancer (global test P = 0.11)
Hap1: TACGCAA	109/358	1.00	131/298	1.47 (1.08–1.99)	0.01
Hap2: TGTACAA	183/542	1.00	80/269	0.72 (0.52–0.98)	0.04
Hap3: TGTGTGA	160/387	1.00	51/151	0.91 (0.63–1.31)	0.60
Hap4: CGCGTAG	169/383	1.00	57/114	1.51 (1.04–2.18)	0.03
Hap5: TGCGCAA	197/550	1.00	43/106	1.14 (0.76–1.72)	0.52
Hap6: TGTGCAA	189/505	1.00	14/60	0.59 (0.32–1.11)	0.09
Non-aggressive prostate cancer (global test P = 0.27)
Hap1: TACGCAA	221/358	1.00	198/298	1.08 (0.84–1.39)	0.55
Hap2: TGTACAA	329/542	1.00	183/269	1.11 (0.87–1.43)	0.40
Hap3: TGTGTGA	236/387	1.00	88/151	0.89 (0.65–1.20)	0.44
Hap4: CGCGTAG	257/383	1.00	90/114	1.31 (0.96–1.80)	0.09
Hap5: TGCGCAA	359/550	1.00	60/106	0.85 (0.59–1.22)	0.38
Hap6: TGTGCAA	331/505	1.00	32/60	0.82 (0.52–1.30)	0.40

Aggressive prostate cancer was defined as stages T3b, T4, N1, M1 or death due to prostate cancer or Gleason sum ≥7.

*P-value was for testing the null hypothesis: OR_carriers = OR_non-carriers = 1.